A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including neurocognitive and ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...

Unless you have Wilson's disease, or you know someone who does, you've probably never heard of this rare genetic condition.

Irvine-based medical device company Beta Bionics Inc. on Jan. 6 filed an S-1 with the Securities and Exchange Commission to ...

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.